Last reviewed · How we verify
KHK4827
KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.
KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway. Used for Thromboembolism prevention (in development).
At a glance
| Generic name | KHK4827 |
|---|---|
| Also known as | Brodalumab |
| Sponsor | Kyowa Kirin Co., Ltd. |
| Drug class | Factor XIa inhibitor |
| Target | Factor XIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
KHK4827 selectively inhibits Factor XIa, an enzyme involved in the contact phase of blood coagulation. By blocking Factor XIa, the drug reduces the amplification of thrombin generation while potentially preserving hemostasis through the extrinsic pathway, which may provide a favorable safety profile compared to conventional anticoagulants.
Approved indications
- Thromboembolism prevention (in development)
Common side effects
Key clinical trials
- A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis (PHASE3)
- A Study of KHK4827 in Patients With Systemic Sclerosis (PHASE1)
- A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea (PHASE3)
- A Phase 3 Clinical Study of KHK 4827 (PHASE3)
- A Study of KHK4827 in Subjects With Palmoplantar Pustulosis (PHASE3)
- A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis (PHASE4)
- An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis (PHASE3)
- A Phase 3 Clinical Study of KHK4827 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KHK4827 CI brief — competitive landscape report
- KHK4827 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI